NCT03934333View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

September 10, 2019

Study Completion Date

September 10, 2019

Conditions
Relative Bioavailability
Interventions
DRUG

BDA MDI 160/180 mcg

Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.

DRUG

Pulmicort Flexhaler 180 mcg

Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY